
<html>

<head>





</head>

<body lang="EN-US" link="blue" vlink="purple">

<div style="font-family:Times New Roman;">

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1</font></b></p>

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">FDA Issues Not Approvable Letter to Cellegy
Pharmaceuticals<br>
for Cellegesic<sup>TM</sup></font></b></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:normal;">&nbsp;</font></b></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SOUTH SAN
FRANCISCO, CA &#150; </font></b>December&nbsp;23, 2004 &#150; Cellegy
Pharmaceuticals, Inc. (Nasdaq:&#160; CLGY)
announced that it received late today a communication from the U.S. Food and
Drug Administration in the form of a Not Approvable Letter for its product
Cellegesic<sup>TM</sup> (nitroglycerin ointment).&#160; Cellegesic was the subject of an NDA that was
filed with the FDA for the treatment of pain associated with chronic anal
fissure.&#160; In October&nbsp;the FDA granted
the application a Priority Review status.</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">K. Michael Forrest,
Cellegy&#146;s President and CEO, stated, &#147;We believe that our third Phase 3 trial
achieved the requirements for approval of Cellegesic as agreed with the FDA
under the provisions of a Special Protocol Assessment.&#160; In addition, two previous Phase 3 trials
included in the NDA were supportive of approval.&#160; The FDA reached a different conclusion and
has raised several issues that were not part of the agreed upon approval
criteria.&#160; We are evaluating the FDA&#146;s
letter and will carefully consider all of our options.&#148;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;We are disappointed that
the FDA chose to take this action on what we consider to be a safe and
effective product that could provide relief to hundreds of thousands of people
suffering from this very painful condition,&#148; said David A. Karlin, M.D.,
Cellegy&#146;s Vice President, Clinical Research.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<h1 style="margin:0in 0in .0001pt;page-break-after:auto;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">About Cellegy Pharmaceuticals</font></b></h1>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cellegy Pharmaceuticals
is a specialty biopharmaceutical company that develops and commercializes prescription
drugs for the treatment of gastrointestinal disorders, women&#146;s health care
conditions, including sexual dysfunction and HIV prevention, and certain
cancers.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cellegesic, branded &#147;Rectogesic<sup>TM</sup>&#148;
outside the United States, is approved in the United Kingdom for the treatment
of pain associated with chronic anal fissures.&#160;
Launch of Rectogesic in the United Kingdom through ProStrakan Group
Limited, Cellegy&#146;s corporate partner, is expected in the first half of 2005.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company is also
pursuing the use of Cellegesic for the treatment of hemorrhoids, as well as
dyspareunia, a painful condition that prevents or inhibits sexual intercourse
in more than 5 million women in the United States.&#160; Currently, there is no effective treatment
for dyspareunia.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cellegy recently enhanced
its women&#146;s healthcare product portfolio through the acquisition of Biosyn and
its lead product Savvy<sup>TM</sup>, a contraceptive gel to prevent HIV-AIDS in
women.&#160; Savvy is in advanced Phase 3
clinical trials for contraception and for</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\ssriniv\04-15336-1\task262472\15336-1-mm.htm',USER='Sriraman',CD='Dec 24 07:35 2004' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the prevention of
HIV.&#160; Cellegy is also developing
Tostrelle<sup>TM</sup> Gel for the treatment of sexual dysfunction (libido) in
postmenopausal women and is planning to enter Phase 3 clinical trials during
2005.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fortigel<sup>TM</sup>,
branded Tostrex<sup>TM</sup> outside the United States, is currently undergoing
regulatory review in Sweden for the treatment of male hypogonadism caused by
testosterone deficiency.&#160; ProStrakan has
also licensed rights to Tostrex for the United Kingdom and other European markets.&#160; Cellegy is in discussions with the FDA to
determine the final design of a Phase 3 trial required for marketing approval
of Fortigel in the United States.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other products being
developed by Cellegy researchers address a number of conditions including
prostate cancer, Raynaud&#146;s Disease and Restless Leg Syndrome.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\ssriniv\04-15336-1\task262472\15336-1-mm.htm',USER='Sriraman',CD='Dec 24 07:35 2004' -->


</body>

</html>

